Choosing the right cell model is half the battle won in your disease research and drug screening endeavors. Drug screening is a pivotal step in modern drug development processes, involving standardized experimental methods to sift through vast compounds and identify potential drug candidates with high activity against specific targets.  Developing a new drug typically spans over a decade and entails substantial investments. Globally, over $30 billion is invested annually in new drugs, yet statistically, only one out of a million compounds eventually receive FDA approval for market launch, with only 30% of launched drugs recovering their R&D costs. Consequently, pharmaceutical companies place paramount importance on the efficiency and accuracy of their drug screening processes to reduce costs and accelerate drug development timelines.

Early in drug development, besides direct testing against known targets, cellular biological models play a crucial role throughout the screening process. Early elimination of negative compounds and identification of high-quality lead compounds are critical steps in drug screening that significantly mitigate development costs and risks.

Creative Biogene is a leader in cell biology, providing cutting-edge cell-level testing solutions for drug discovery. We provide comprehensive cell screening and analysis services, including drug activity evaluation, ADME and pharmacokinetic testing, drug toxicity evaluation, etc. These services help to screen out negative compounds at an early stage and quickly identify high-quality lead compounds, thereby reducing development costs and risks.